中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2013年
5期
640-642
,共3页
黄芩甙/药理学%喉肿瘤/病理学%喉肿瘤/药物疗法%肿瘤细胞,培养的%基质金属蛋白酶类%血管内皮生长因子类%成纤维细胞生长因子2%细胞运动
黃芩甙/藥理學%喉腫瘤/病理學%喉腫瘤/藥物療法%腫瘤細胞,培養的%基質金屬蛋白酶類%血管內皮生長因子類%成纖維細胞生長因子2%細胞運動
황금대/약이학%후종류/병이학%후종류/약물요법%종류세포,배양적%기질금속단백매류%혈관내피생장인자류%성섬유세포생장인자2%세포운동
BAICALIN/pharmacology%Laryngeal neoplasms/pathology%Laryngeal neoplasms/ drug therapy%Tumor cells,cultured%Matrix metalloproteinases%Vascular endothelial growth factors%Fibroblast growth factor 2%Cell movement
目的 探讨黄芩苷对人喉癌Hep-2细胞血管生成调节因子[基质金属蛋白酶(matrix metalloproteinase,MMP)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、碱性成纤维细胞生长因子(basic fibroblast growth factor,bFGF)]表达及迁移能力的影响.方法 体外培养Hep-2细胞,(1)加入佛波脂诱导,明胶酶谱法和Transwell小室分别观察不同浓度黄芩苷对Hep-2细胞MMP表达水平及迁移能力的影响；(2)不加佛波脂,酶联免疫吸附测定(ELISA)法观察不同浓度黄芩苷对细胞VEGF和bFGF蛋白含量的影响.结果 黄芩苷低、中、高剂量组MMP-3酶活性[(95.0±4.9)％、(93.1±6.2)％、(90.7±7.3)％ vs (100.0±0.0)％,t=2.123,2.309,2.412,P＜0.05]、MMP-9酶活性[(92.3±7.5)％、(89.5±9.3)％、(85.6±6.1)％ vs (100.0±0.0)％,t =2.253,2.302,3.708,P ＜0.05或P＜0.01]、VEGF蛋白含量[(230.6±12.7)ng/L、(212.1±15.9)ng/L、(184.2±23.5)ng/L vs(242.7±9.5)ng/L,t=2.408,3.733,4.146,P＜0.05或P＜0.01]、bFGF蛋白含量[(181.2±13.0) ng/L、(169.9±17.3) ng/L、(140.7±9.2)ng/Lvs (190.7±8.2)ng/L,t=2.330,2.922,5.145,P＜0.05或P＜0.01]及细胞迁移率[(32.9±7.1)％、(27.9±4.4)％、(23.3±6.0)％vs(38.3±5.6)％,t=2.141,3.365,4.027,P＜0.05或P＜0.01]与对照组比较,差异均有统计学意义.结论 通过抑制血管生成调节因子的表达,黄芩苷可有效抑制人喉癌Hep-2细胞的迁移能力,可能用于喉癌的治疗.
目的 探討黃芩苷對人喉癌Hep-2細胞血管生成調節因子[基質金屬蛋白酶(matrix metalloproteinase,MMP)、血管內皮生長因子(vascular endothelial growth factor,VEGF)、堿性成纖維細胞生長因子(basic fibroblast growth factor,bFGF)]錶達及遷移能力的影響.方法 體外培養Hep-2細胞,(1)加入彿波脂誘導,明膠酶譜法和Transwell小室分彆觀察不同濃度黃芩苷對Hep-2細胞MMP錶達水平及遷移能力的影響；(2)不加彿波脂,酶聯免疫吸附測定(ELISA)法觀察不同濃度黃芩苷對細胞VEGF和bFGF蛋白含量的影響.結果 黃芩苷低、中、高劑量組MMP-3酶活性[(95.0±4.9)％、(93.1±6.2)％、(90.7±7.3)％ vs (100.0±0.0)％,t=2.123,2.309,2.412,P＜0.05]、MMP-9酶活性[(92.3±7.5)％、(89.5±9.3)％、(85.6±6.1)％ vs (100.0±0.0)％,t =2.253,2.302,3.708,P ＜0.05或P＜0.01]、VEGF蛋白含量[(230.6±12.7)ng/L、(212.1±15.9)ng/L、(184.2±23.5)ng/L vs(242.7±9.5)ng/L,t=2.408,3.733,4.146,P＜0.05或P＜0.01]、bFGF蛋白含量[(181.2±13.0) ng/L、(169.9±17.3) ng/L、(140.7±9.2)ng/Lvs (190.7±8.2)ng/L,t=2.330,2.922,5.145,P＜0.05或P＜0.01]及細胞遷移率[(32.9±7.1)％、(27.9±4.4)％、(23.3±6.0)％vs(38.3±5.6)％,t=2.141,3.365,4.027,P＜0.05或P＜0.01]與對照組比較,差異均有統計學意義.結論 通過抑製血管生成調節因子的錶達,黃芩苷可有效抑製人喉癌Hep-2細胞的遷移能力,可能用于喉癌的治療.
목적 탐토황금감대인후암Hep-2세포혈관생성조절인자[기질금속단백매(matrix metalloproteinase,MMP)、혈관내피생장인자(vascular endothelial growth factor,VEGF)、감성성섬유세포생장인자(basic fibroblast growth factor,bFGF)]표체급천이능력적영향.방법 체외배양Hep-2세포,(1)가입불파지유도,명효매보법화Transwell소실분별관찰불동농도황금감대Hep-2세포MMP표체수평급천이능력적영향；(2)불가불파지,매련면역흡부측정(ELISA)법관찰불동농도황금감대세포VEGF화bFGF단백함량적영향.결과 황금감저、중、고제량조MMP-3매활성[(95.0±4.9)％、(93.1±6.2)％、(90.7±7.3)％ vs (100.0±0.0)％,t=2.123,2.309,2.412,P＜0.05]、MMP-9매활성[(92.3±7.5)％、(89.5±9.3)％、(85.6±6.1)％ vs (100.0±0.0)％,t =2.253,2.302,3.708,P ＜0.05혹P＜0.01]、VEGF단백함량[(230.6±12.7)ng/L、(212.1±15.9)ng/L、(184.2±23.5)ng/L vs(242.7±9.5)ng/L,t=2.408,3.733,4.146,P＜0.05혹P＜0.01]、bFGF단백함량[(181.2±13.0) ng/L、(169.9±17.3) ng/L、(140.7±9.2)ng/Lvs (190.7±8.2)ng/L,t=2.330,2.922,5.145,P＜0.05혹P＜0.01]급세포천이솔[(32.9±7.1)％、(27.9±4.4)％、(23.3±6.0)％vs(38.3±5.6)％,t=2.141,3.365,4.027,P＜0.05혹P＜0.01]여대조조비교,차이균유통계학의의.결론 통과억제혈관생성조절인자적표체,황금감가유효억제인후암Hep-2세포적천이능력,가능용우후암적치료.
Objective To explore the effects of bacailin on the angiogenic regulating factor and migration activity of laryngeal cancer cells.Methods Hep-2 was cultured in vitro,(1)in the groups adding phorbol ester,gelatin-zymogram and Transwell assay were used to observe the effects of bacailin on the gelatinase activity of matrix metalloproteinase (MMP) and the migration ability of Hep-2,respectively; (2)in the group without phorbol ester,enzyme-linked immunosorbent assay (ELISA) was used to detect the effects of bacailin on the protein level of endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).Results Among the control group,the low-dose group,the middle-dose group,and the high-dose group,the activity of MMP-3 of each corresponding group was (100.0 ±0.0) ％,(95.0 ±4.9) ％,(93.1± 6.2)％,and (90.7 ± 7.3)％ with statistically significant difference (t =2.123,2.309,2.412,P ＜0.05) ; the activity of MMP-9 of each corresponding group was (100.0 ± 0.0) ％,(92.3 ± 7.5) ％,(89.5 ± 9.3) ％,and (85.6 ± 6.1) ％ with statistically significant difference (t =2.253,2.302,3.708,P ＜0.05 or P ＜0.01) ;the protein level of VEGF of each corresponding group was (242.7 ±9.5)ng/L,(230.6 ± 12.7)ng/L,(212.1 ± 15.9)ng/L,and (184.2 ± 23.5)ng/L with statistically significant difference (t =2.408,3.733,4.146,P ＜0.05 or P ＜0.01) ; the protein level of bFGF of each corresponding group was (190.7±8.2) ng/L,(181.2±13.0) ng/L,(169.9±17.3)ng/L,and (140.7±9.2)ng/Lwith statistically significant difference (t =2.330,2.922,5.145,P ＜0.05 or P ＜0.01) ; Cellular migration rate of each corresponding group was (38.3 ± 5.6) ％,(32.9 ± 7.1) ％,(27.9 ± 4.4) ％,and (23.3 ± 6.0) ％ with statistically significant difference (t =2.141,3.365,4.027,P ＜ 0.05 or P ＜0.01).Conclusions Bacailin could suppress the migration of Hep-2 through inhibiting expression of angiogenic regulating factor,which might has clinical value in the treatment of laryngeal cancer.
